These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25966348)

  • 1. Endothelin antagonism and hypertension: an evolving target.
    Laffin LJ; Bakris GL
    Semin Nephrol; 2015 Mar; 35(2):168-75. PubMed ID: 25966348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update.
    Blazek O; Bakris GL
    Eur J Pharmacol; 2024 Sep; 979():176752. PubMed ID: 39047966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptors, renal effects and blood pressure.
    Boesen EI
    Curr Opin Pharmacol; 2015 Apr; 21():25-34. PubMed ID: 25544397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin, kidney disease, and hypertension.
    Speed JS; Pollock DM
    Hypertension; 2013 Jun; 61(6):1142-5. PubMed ID: 23608655
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.
    Yuan W; Cheng G; Li B; Li Y; Lu S; Liu D; Xiao J; Zhao Z
    Blood Press; 2017 Jun; 26(3):139-149. PubMed ID: 27808564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Endothelin Receptor Antagonists in Hypertension.
    Burnier M
    Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin Receptor Antagonists: New Hope for Renal Protection?
    Tobe S; Kohan DE; Singarayer R
    Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelin in hypertension.
    Schiffrin EL
    Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.
    Heidari Nejad S; Azzam O; Schlaich MP
    Future Cardiol; 2024; 20(9):435-445. PubMed ID: 38953510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From ABCD to E for endothelin in resistant hypertension.
    Abraham GR; Davenport AP
    Cell; 2023 Jan; 186(2):240-242. PubMed ID: 36603580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin in hypertension.
    Schiffrin EL
    Curr Opin Cardiol; 1995 Sep; 10(5):485-94. PubMed ID: 7496057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin antagonists and resistant hypertension in chronic kidney disease.
    Moore R; Linas S
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):432-6. PubMed ID: 20502329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
    El-Mas MM; Helmy MW; Ali RM; El-Gowelli HM
    Toxicol Appl Pharmacol; 2015 Apr; 284(1):1-7. PubMed ID: 25656942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.
    Reichetzeder C; Tsuprykov O; Hocher B
    Life Sci; 2014 Nov; 118(2):141-8. PubMed ID: 24607774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin in hypertension: a role for receptor antagonists?
    Moreau P
    Cardiovasc Res; 1998 Sep; 39(3):534-42. PubMed ID: 9861294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females.
    Gillis EE; Sasser JM; Sullivan JC
    Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R691-6. PubMed ID: 26936781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders.
    Goddard J; Webb DJ
    Drugs R D; 1999 Jul; 2(1):1-12. PubMed ID: 10560541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.
    Enseleit F; Lüscher TF; Ruschitzka F
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):231-40. PubMed ID: 20660536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.